- Home
- FURY vs MIST Comparison
FURY vs MIST Comparison
Compare FURY & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FURY
- MIST
- Stock Information
- Founded
- FURY 2008
- MIST 2003
- Country
- FURY Canada
- MIST Canada
- Employees
- FURY N/A
- MIST N/A
- Industry
- FURY Precious Metals
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- FURY Basic Materials
- MIST Health Care
- Exchange
- FURY Nasdaq
- MIST Nasdaq
- Market Cap
- FURY 91.4M
- MIST 89.8M
- IPO Year
- FURY N/A
- MIST N/A
- Fundamental
- Price
- FURY $0.50
- MIST $1.92
- Analyst Decision
- FURY Strong Buy
- MIST Strong Buy
- Analyst Count
- FURY 1
- MIST 2
- Target Price
- FURY $1.20
- MIST $7.50
- AVG Volume (30 Days)
- FURY 347.7K
- MIST 613.1K
- Earning Date
- FURY 08-07-2025
- MIST 08-07-2025
- Dividend Yield
- FURY N/A
- MIST N/A
- EPS Growth
- FURY N/A
- MIST N/A
- EPS
- FURY N/A
- MIST N/A
- Revenue
- FURY N/A
- MIST N/A
- Revenue This Year
- FURY N/A
- MIST N/A
- Revenue Next Year
- FURY N/A
- MIST N/A
- P/E Ratio
- FURY N/A
- MIST N/A
- Revenue Growth
- FURY N/A
- MIST N/A
- 52 Week Low
- FURY $0.35
- MIST $0.63
- 52 Week High
- FURY $0.56
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- FURY 54.96
- MIST 67.01
- Support Level
- FURY $0.47
- MIST $1.85
- Resistance Level
- FURY $0.52
- MIST $2.02
- Average True Range (ATR)
- FURY 0.03
- MIST 0.09
- MACD
- FURY -0.01
- MIST 0.01
- Stochastic Oscillator
- FURY 28.22
- MIST 73.75
About FURY Fury Gold Mines Limited
Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).